Drug Discovery & Development | Curis, Debiopharm Report Anti-Tumor Activity, Synergy with Debio 0932 Drug Discovery & Development Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in a Phase 1 trial in combination with everolimus, an mTOR inhibitor, in advanced RCC patients. In a high throughput ... Curis and Debiopharm Group Report Preclinical Data for Debio 0932 at AACR ... Curis and Debiopharm Group(TM) Report Preclinical Data for Debio 0932 at ... |
